{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nCoiled‐coil domain‐containing 58 (CCDC58), here referred to as MIX23, is emerging as a robust pan-cancer biomarker with multifaceted roles in tumor progression. Comprehensive analyses across multiple databases (TCGA, GTEx, UALCAN, among others) have revealed that MIX23 is significantly overexpressed at both the mRNA and protein levels in various malignancies—including hepatocellular carcinoma and breast cancer—with its upregulation correlating with poor patient prognosis and increased tumor heterogeneity. Alterations such as heightened mutation frequency and reduced methylation of key sites further suggest that MIX23 is intimately tied to genomic instability, while its association with DNA methyltransferases and mismatch repair genes underscores its potential involvement in the maintenance of genomic integrity."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nMoreover, functional studies indicate that MIX23 plays an essential role in facilitating tumor cell proliferation, migration, and invasion. Enrichment analyses have connected MIX23-related gene networks to critical cellular processes including mitosis, chromosome dynamics, and cell cycle control. Its impact on the tumor microenvironment is further evidenced by its negative correlations with immune and stromal scores and its notable associations with various immune cell populations such as NK T cells, Tregs, and CAFs; this interplay with the immune landscape renders MIX23 a promising marker not only for prognosis but also for predicting immunotherapy responsiveness. These collective findings advocate for the potential of MIX23 as both a diagnostic indicator and a therapeutic target in pan-cancer management."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "2"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Huili Wu, Qing Geng, Wenxiang Shi, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Comprehensive pan-cancer analysis reveals CCDC58 as a carcinogenic factor related to immune infiltration."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Apoptosis (2024)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1007/s10495-023-01919-0"}], "href": "https://doi.org/10.1007/s10495-023-01919-0"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "38066393"}], "href": "https://pubmed.ncbi.nlm.nih.gov/38066393"}]}, {"type": "r", "ref": 2, "children": [{"type": "t", "text": "Kai Yang, Yan Ma, Weigang Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "CCDC58 is a potential biomarker for diagnosis, prognosis, immunity, and genomic heterogeneity in pan-cancer."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Sci Rep (2024)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1038/s41598-024-59154-9"}], "href": "https://doi.org/10.1038/s41598-024-59154-9"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "38609450"}], "href": "https://pubmed.ncbi.nlm.nih.gov/38609450"}]}]}]}